1.
J Med Chem
; 52(21): 6535-8, 2009 Nov 12.
Artículo
en Inglés
| MEDLINE
| ID: mdl-19835382
RESUMEN
Our efforts to discover potent, orally bioavailable type II calcimimetic agents for the treatment of secondary hyperparathyroidism focused on the development of ring constrained analogues of the known calcimimetic R-568. The structure-activity relationships of various substituted heterocycles and their effects on the human calcium-sensing receptor are discussed. Pyrazole 15 was shown to be efficacious in a rat in vivo pharmacodynamic model.